Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Basic) (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EPS (Basic) for 13 consecutive years, with $1.2 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 487.1% to $1.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.09 through Dec 2025, up 281.74% year-over-year, with the annual reading at $2.1 for FY2025, 282.61% up from the prior year.
  • EPS (Basic) for Q4 2025 was $1.2 at Theravance Biopharma, up from $0.07 in the prior quarter.
  • The five-year high for EPS (Basic) was $12.14 in Q3 2022, with the low at -$1.24 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.4, with a median of -$0.28 recorded in 2023.
  • The sharpest move saw EPS (Basic) skyrocketed 1697.37% in 2022, then crashed 101.4% in 2023.
  • Over 5 years, EPS (Basic) stood at -$0.43 in 2021, then soared by 51.16% to -$0.21 in 2022, then increased by 19.05% to -$0.17 in 2023, then plummeted by 82.35% to -$0.31 in 2024, then skyrocketed by 487.1% to $1.2 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $1.2, $0.07, and $1.09 for Q4 2025, Q3 2025, and Q2 2025 respectively.